|
2012-12-27 |
2012-12-24 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
17 173
+36.3%
107,42
1 167 020 $US
|
17 173
+36.3%
|
107,42
|
1 167 020 $US
|
|
|
2012-12-17 |
2012-12-13 |
V
Vente
|
BROOKE PAUL A
Administrateur non-exécutif
|
83 706
+48.4%
40,82
4 409 792 $US
|
83 706
+48.4%
|
40,82
|
4 409 792 $US
|
|
|
2012-12-12 |
2012-12-10 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
56 638
-12.4%
368,19
3 170 795 $US
|
56 638
-12.4%
|
368,19
|
3 170 795 $US
|
|
|
2012-12-12 |
2012-12-10 |
V
Vente
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
50 000
-57.0%
24,07
1 203 360 $US
|
50 000
-57.0%
|
24,07
|
1 203 360 $US
|
|
|
2012-12-12 |
2012-12-10 |
V
Vente
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
10 000
-21.0%
24,07
240 672 $US
|
10 000
-21.0%
|
24,07
|
240 672 $US
|
|
|
2012-12-05 |
2012-12-03 |
V
Vente
|
Wolf John Peter III
VP, General Counsel
Dirigeant
|
18 000
-100.0%
24,85
447 257 $US
|
18 000
-100.0%
|
24,85
|
447 257 $US
|
|
|
2012-12-05 |
2012-12-03 |
A
Achat
|
DOUGHERTY MICHAEL R
Administrateur non-exécutif
|
2 500
+55.6%
25,07
62 675 $US
|
2 500
+55.6%
|
25,07
|
62 675 $US
|
|
|
2012-12-05 |
2012-12-03 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
10 000
-18.3%
24,80
248 000 $US
|
10 000
-18.3%
|
24,80
|
248 000 $US
|
|
|
2012-12-04 |
2012-11-30 |
V
Vente
|
GLASER ROBERT
Administrateur non-exécutif
|
10 000
-19.5%
24,78
247 795 $US
|
10 000
-19.5%
|
24,78
|
247 795 $US
|
|
|
2012-12-04 |
2012-11-30 |
V
Vente
|
GLASER ROBERT
Administrateur non-exécutif
|
20 000
-32.6%
24,78
495 590 $US
|
20 000
-32.6%
|
24,78
|
495 590 $US
|
|
|
2012-11-30 |
2012-11-28 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
15 000
-21.6%
24,22
363 326 $US
|
15 000
-21.6%
|
24,22
|
363 326 $US
|
|
|
2012-11-30 |
2012-11-28 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
2 500
-4.4%
24,22
60 554 $US
|
2 500
-4.4%
|
24,22
|
60 554 $US
|
|
|
2012-11-15 |
2012-11-13 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
12 500
-18.7%
25,01
312 585 $US
|
12 500
-18.7%
|
25,01
|
312 585 $US
|
|
|
2012-11-15 |
2012-11-13 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
10 000
-15.5%
24,84
248 426 $US
|
10 000
-15.5%
|
24,84
|
248 426 $US
|
|
|
2012-11-13 |
2012-11-08 |
V
Vente
|
MILANO VINCENT
President and CEO
Administrateur exécutif
|
41 418
-30.5%
24,54
1 016 522 $US
|
41 418
-30.5%
|
24,54
|
1 016 522 $US
|
|
|
2012-11-13 |
2012-11-08 |
V
Vente
|
MILANO VINCENT
President and CEO
Administrateur exécutif
|
42 000
-30.8%
24,54
1 030 806 $US
|
42 000
-30.8%
|
24,54
|
1 030 806 $US
|
|
|
2012-11-05 |
2012-11-02 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
10 000
-15.5%
25,37
253 703 $US
|
10 000
-15.5%
|
25,37
|
253 703 $US
|
|
|
2012-06-13 |
2012-06-11 |
V
Vente
|
CLAYPOOL WILLIAM D MD
Administrateur non-exécutif
|
10 000
-13.4%
20,04
200 430 $US
|
10 000
-13.4%
|
20,04
|
200 430 $US
|
|
|
2012-03-27 |
2012-03-23 |
PlS
Vente planifiée
|
Pietrusko Robert
VP, Regulatory & Quality
Dirigeant
|
20 000
-82.9%
30,00
600 000 $US
|
20 000
-82.9%
|
30,00
|
600 000 $US
|
|
|
2012-03-12 |
2012-03-09 |
V
Vente
|
Morris Richard Steven
Chief Accounting Officer
Dirigeant
|
1 300
-51.1%
29,71
38 618 $US
|
1 300
-51.1%
|
29,71
|
38 618 $US
|
|
|
2012-03-12 |
2012-03-09 |
V
Vente
|
Fletcher Robert C.
V.P., Business Development
Dirigeant
|
32 000
-99.3%
29,65
948 954 $US
|
32 000
-99.3%
|
29,65
|
948 954 $US
|
|
|
2012-03-07 |
2012-03-05 |
V
Vente
|
Morris Richard Steven
Chief Accounting Officer
Dirigeant
|
5 300
-81.0%
33,01
174 953 $US
|
5 300
-81.0%
|
33,01
|
174 953 $US
|
|
|
2012-03-07 |
2012-03-05 |
V
Vente
|
DOYLE THOMAS F
VP Strategic Initiatives
Dirigeant
|
210 000
-80.0%
32,48
6 820 212 $US
|
210 000
-80.0%
|
32,48
|
6 820 212 $US
|
|
|
2012-03-06 |
2012-03-01 |
V
Vente
|
SOLAND DANIEL B
VP, Chief Operating Officer
Dirigeant
|
30 000
-41.2%
32,99
989 700 $US
|
30 000
-41.2%
|
32,99
|
989 700 $US
|
|
|
2012-03-05 |
2012-03-01 |
V
Vente
|
Rowland Charles A Jr
VP, Chief Financial Officer
Dirigeant
|
12 750
-42.7%
32,11
409 434 $US
|
12 750
-42.7%
|
32,11
|
409 434 $US
|
|
|
2012-03-05 |
2012-03-01 |
V
Vente
|
Rowland Charles A Jr
VP, Chief Financial Officer
Dirigeant
|
70 000
-70.1%
32,12
2 248 197 $US
|
70 000
-70.1%
|
32,12
|
2 248 197 $US
|
|
|
2011-12-16 |
2011-12-14 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
50 566
+2.6%
27,29
1 379 860 $US
|
50 566
+2.6%
|
27,29
|
1 379 860 $US
|
|
|
2011-12-16 |
2011-12-14 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
291 706
+3.1%
27,29
7 960 161 $US
|
291 706
+3.1%
|
27,29
|
7 960 161 $US
|
|
|
2011-12-16 |
2011-12-14 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
7 828
+2.6%
27,29
213 613 $US
|
7 828
+2.6%
|
27,29
|
213 613 $US
|
|
|
2011-12-15 |
2011-12-14 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
25 000
-56.3%
25,17
629 250 $US
|
25 000
-56.3%
|
25,17
|
629 250 $US
|
|
|
2011-12-15 |
2011-12-14 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
25 000
-56.3%
25,50
637 500 $US
|
25 000
-56.3%
|
25,50
|
637 500 $US
|
|
|
2011-12-14 |
2011-12-13 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
22 330
-53.5%
23,50
524 755 $US
|
22 330
-53.5%
|
23,50
|
524 755 $US
|
|
|
2011-12-14 |
2011-12-12 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
17 670
-47.6%
23,50
415 317 $US
|
17 670
-47.6%
|
23,50
|
415 317 $US
|
|
|
2011-12-05 |
2011-12-01 |
V
Vente
|
DOYLE THOMAS F
VP Strategic Initiatives
Dirigeant
|
10 000
-16.0%
23,82
238 159 $US
|
10 000
-16.0%
|
23,82
|
238 159 $US
|
|
|
2011-12-01 |
2011-11-30 |
PlS
Vente planifiée
|
Pietrusko Robert
VP, Regulatory & Quality
Dirigeant
|
20 000
-83.6%
24,00
480 000 $US
|
20 000
-83.6%
|
24,00
|
480 000 $US
|
|
|
2011-11-29 |
2011-11-28 |
PlS
Vente planifiée
|
Pietrusko Robert
VP, Regulatory & Quality
Dirigeant
|
19 000
-82.9%
23,00
437 000 $US
|
19 000
-82.9%
|
23,00
|
437 000 $US
|
|
|
2011-11-29 |
2011-11-28 |
V
Vente
|
GLASER ROBERT
Administrateur non-exécutif
|
5 000
-11.9%
23,00
115 000 $US
|
5 000
-11.9%
|
23,00
|
115 000 $US
|
|
|
2011-11-28 |
2011-11-23 |
PlS
Vente planifiée
|
Pietrusko Robert
VP, Regulatory & Quality
Dirigeant
|
1 000
-25.6%
23,00
23 000 $US
|
1 000
-25.6%
|
23,00
|
23 000 $US
|
|
|
2011-11-23 |
2011-11-21 |
PlS
Vente planifiée
|
MILANO VINCENT
President and CEO
Administrateur exécutif
|
41 691
-35.4%
22,53
939 127 $US
|
41 691
-35.4%
|
22,53
|
939 127 $US
|
|
|
2011-11-23 |
2011-11-21 |
PlS
Vente planifiée
|
MILANO VINCENT
President and CEO
Administrateur exécutif
|
19 996
-20.8%
22,53
450 428 $US
|
19 996
-20.8%
|
22,53
|
450 428 $US
|
|
|
2011-11-23 |
2011-11-21 |
PlS
Vente planifiée
|
MILANO VINCENT
President and CEO
Administrateur exécutif
|
15 000
-16.4%
22,53
337 888 $US
|
15 000
-16.4%
|
22,53
|
337 888 $US
|
|
|
2011-11-17 |
2011-11-16 |
V
Vente
|
Morris Richard Steven
Chief Accounting Officer
Dirigeant
|
2 000
-63.2%
22,59
45 181 $US
|
2 000
-63.2%
|
22,59
|
45 181 $US
|
|
|
2011-11-15 |
2011-11-14 |
PlS
Vente planifiée
|
Pietrusko Robert
VP, Regulatory & Quality
Dirigeant
|
20 000
-83.6%
22,00
440 000 $US
|
20 000
-83.6%
|
22,00
|
440 000 $US
|
|
|
2011-11-09 |
2011-11-07 |
V
Vente
|
Wolf John Peter III
VP, General Counsel
Dirigeant
|
12 250
-100.0%
21,08
258 194 $US
|
12 250
-100.0%
|
21,08
|
258 194 $US
|
|
|
2011-11-08 |
2011-11-07 |
V
Vente
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
200
-1.0%
21,01
4 202 $US
|
200
-1.0%
|
21,01
|
4 202 $US
|
|
|
2011-11-08 |
2011-11-07 |
V
Vente
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
19 800
-50.2%
21,00
415 800 $US
|
19 800
-50.2%
|
21,00
|
415 800 $US
|
|
|
2011-11-02 |
2011-11-01 |
PlS
Vente planifiée
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
24 121
-55.4%
20,05
483 641 $US
|
24 121
-55.4%
|
20,05
|
483 641 $US
|
|
|
2011-11-02 |
2011-10-31 |
V
Vente
|
Broom Colin MD
VP & Chief Scientific Officer
Dirigeant
|
20 495
-51.3%
20,42
418 555 $US
|
20 495
-51.3%
|
20,42
|
418 555 $US
|
|
|
2011-10-06 |
2011-10-05 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
145 763
+1.6%
18,18
2 650 423 $US
|
145 763
+1.6%
|
18,18
|
2 650 423 $US
|
|
|
2011-10-06 |
2011-10-05 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
16 278
+0.9%
18,18
295 985 $US
|
16 278
+0.9%
|
18,18
|
295 985 $US
|
|
|
2011-10-06 |
2011-10-05 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
6 017
+2.1%
18,18
109 408 $US
|
6 017
+2.1%
|
18,18
|
109 408 $US
|
|
|
2011-10-06 |
2011-10-04 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
45 584
+0.5%
17,48
796 644 $US
|
45 584
+0.5%
|
17,48
|
796 644 $US
|
|
|
2011-10-06 |
2011-10-04 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
2 511
+0.1%
17,48
43 883 $US
|
2 511
+0.1%
|
17,48
|
43 883 $US
|
|
|
2011-10-06 |
2011-10-04 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
1 905
+0.7%
17,48
33 293 $US
|
1 905
+0.7%
|
17,48
|
33 293 $US
|
|
|
2011-10-03 |
2011-10-03 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
445 574
+5.0%
17,71
7 890 269 $US
|
445 574
+5.0%
|
17,71
|
7 890 269 $US
|
|
|
2011-10-03 |
2011-10-03 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
70 629
+0.8%
17,62
1 244 589 $US
|
70 629
+0.8%
|
17,62
|
1 244 589 $US
|
|
|
2011-10-03 |
2011-09-30 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
88 657
+1.0%
18,08
1 602 892 $US
|
88 657
+1.0%
|
18,08
|
1 602 892 $US
|
|
|
2011-10-03 |
2011-09-30 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
43 321
+0.5%
18,19
788 122 $US
|
43 321
+0.5%
|
18,19
|
788 122 $US
|
|
|
2011-10-03 |
2011-09-30 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
13 576
+0.7%
18,08
245 450 $US
|
13 576
+0.7%
|
18,08
|
245 450 $US
|
|
|
2011-10-03 |
2011-09-30 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
6 634
+0.4%
18,19
120 690 $US
|
6 634
+0.4%
|
18,19
|
120 690 $US
|
|
|
2011-10-03 |
2011-09-30 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
3 367
+1.2%
18,08
60 874 $US
|
3 367
+1.2%
|
18,08
|
60 874 $US
|
|
|
2011-10-03 |
2011-09-30 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
1 645
+0.6%
18,19
29 927 $US
|
1 645
+0.6%
|
18,19
|
29 927 $US
|
|
|
2011-10-03 |
2011-09-29 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
159 945
+1.9%
18,00
2 878 882 $US
|
159 945
+1.9%
|
18,00
|
2 878 882 $US
|
|
|
2011-10-03 |
2011-09-29 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
21 117
+1.1%
18,00
380 089 $US
|
21 117
+1.1%
|
18,00
|
380 089 $US
|
|
|
2011-10-03 |
2011-09-29 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
6 084
+2.2%
18,00
109 507 $US
|
6 084
+2.2%
|
18,00
|
109 507 $US
|
|
|
2011-10-03 |
2011-09-29 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
89 970
+1.1%
17,97
1 616 392 $US
|
89 970
+1.1%
|
17,97
|
1 616 392 $US
|
|
|
2011-10-03 |
2011-09-29 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
11 878
+0.6%
17,97
213 399 $US
|
11 878
+0.6%
|
17,97
|
213 399 $US
|
|
|
2011-10-03 |
2011-09-29 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
3 423
+1.3%
17,97
61 497 $US
|
3 423
+1.3%
|
17,97
|
61 497 $US
|
|
|
2011-09-26 |
2011-09-26 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
4 697
+0.3%
18,13
85 155 $US
|
4 697
+0.3%
|
18,13
|
85 155 $US
|
|
|
2011-09-26 |
2011-09-26 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
22 084
+1.2%
18,13
400 295 $US
|
22 084
+1.2%
|
18,13
|
400 295 $US
|
|
|
2011-09-26 |
2011-09-26 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
1 103
+0.4%
18,13
19 997 $US
|
1 103
+0.4%
|
18,13
|
19 997 $US
|
|
|
2011-09-26 |
2011-09-26 |
A
Achat
|
14159 capital (GP), LLC
Actionnaire important
|
5 184
+1.9%
18,13
93 965 $US
|
5 184
+1.9%
|
18,13
|
93 965 $US
|
|
|
2011-09-26 |
2011-09-26 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
28 000
+0.3%
18,13
507 632 $US
|
28 000
+0.3%
|
18,13
|
507 632 $US
|
|
|
2011-09-26 |
2011-09-26 |
A
Achat
|
Baker Brothers Life Sciences Capital (GP), LLC
Actionnaire important
|
131 641
+1.6%
18,13
2 386 125 $US
|
131 641
+1.6%
|
18,13
|
2 386 125 $US
|
|
|
2011-09-26 |
2011-09-23 |
A
Achat
|
Baker Biotech Capital (GP), LLC
Actionnaire important
|
8 828
+0.5%
17,78
156 988 $US
|
8 828
+0.5%
|
17,78
|
156 988 $US
|
|